The study was halted when patient response rates were lower than those seen across a similar trial involving the drug.
Trifluridine plus tipiracil may be an effective treatment option for patients with heavily pretreated metastatic gastric cancer, according to presenters at ESMO 2018.
Pembrolizumab Did Not Improve PFS or OS Compared With Paclitaxel in Relapsed Gastric or Gastroesophageal Junction CancerJune 27, 2018
Results from the KEYNOTE-061 were presented at ESMO World GI 2018.
A recent trial evaluated the safety and efficacy of a DC vaccine combined with salvage chemotherapy.
XP-treated patients with metastatic gastric cancer who had tumors expressing UCK2 and OPRT above a specific threshold survived longer than patients with lower levels of these biomarkers.
Researchers assigned patients with various types of relapsed/refractory cancer to receive escalating doses of JTX-2011 alone or plus nivolumab.
Researchers randomly assigned 1204 patients with gastric adenocarcinoma to undergo omentectomy only or bursectomy.
Researchers randomly assigned 788 patients to receive postoperative chemotherapy or chemoradiotherapy.
Researchers identified 4 classifier genes relevant to gastric cancer in 307 patients in an internal cohort.
Researchers are investigating the efficacy of surgical resection plus HIPEC for improving survival outcomes among patients with gastric cancer.
Researchers are evaluating the safety and efficacy of additional chemotherapy and radiation, alone or with surgery, among patients with esophageal or gastric cancer.
Investigators evaluated data from 277 patients with gastric cancer, 180 of whom underwent CRS plus HIPEC vs 97 who underwent CRS only.
Researchers are evaluating the feasibility and safety of adjuvant HIPEC in patients with locally advanced gastric cancer.
In 2017, new treatment approaches for patients with esophagogastric cancer have been investigated, including novel neoadjuvant regimens and immunotherapies.
Researchers are evaluating the safety and efficacy of FOLFOX plus nab-paclitaxel as a first-line therapy for patients with advanced gastric cancer or adenocarcinoma of the gastroesophageal junction.
Researchers are evaluating the safety and efficacy of PLX9486, a TKI of c-Kit, in combination with pexidartinib (PLX3397) and sunitinib among patients with GIST.
Researchers are investigating the efficacy of pembrolizumab immunotherapy plus chemotherapy as perioperative treatment for patients with gastric cancer or adenocarcinoma of the gastroesophageal junction.
Pembrolizumab monotherapy showed clinical efficacy in patients with advanced gastric cancer.
Perioperative FLOT significantly improved PFS and OS among patients with resectable gastric cancers compared with standard ECF/ECX.
Neoadjuvant FLOT followed by surgery improves outcomes among patients with gastric or gastroesophageal junction cancer.
For this phase 2 trial, researchers are evaluating the efficacy and safety of andecaliximab (GS-5745) and nivolumab vs nivolumab alone.
Patients with operable gastroesophageal cancer with high microsatellite instability did not derive benefit from perioperative chemotherapy.
GEMOX post-surgery adjuvant therapy does not improve relapse-free survival (RFS) among patients with biliary tract cancer.
Bursectomy can be safely performed without increasing the risk of morbidity or mortality among patients with cT3 or cT4 gastric cancer.
The addition of everolimus to paclitaxel did not significantly improve overall response rate, progression-free survival, or overall survival.
For patients with advanced gastric cancer, second-line treatment with ramucirumab is safe and efficacious regardless of age.
Among patients with malignant gastric outlet obstruction caused by gastric cancer, surgical palliation was effective for maintaining patient quality of life.
Omitting surgery and using a watch-and-wait approach does not compromise outcomes for selected patients with advanced rectal cancer.
The FDA has accepted Mylan's Biologics License Application (BLA) for MYL-1401O.
Nivolumab (Opdivo) improved overall survival compared with placebo among patients with unresectable advanced or recurrent gastric cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Changes in Renal Cell Carcinoma Pathologic Staging and Histologic Grading
- Study Identifies Patients With Breast Cancer Who Don't Benefit From Adjuvant Chemo
- CD19 CAR T-Cell Therapies: "Expect an Evolution"
- Hypofractionated WBI Found Noninferior to Conventionally Fractionated WBI
- Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma
- Younger Breast Cancer Patients at Higher Risk for Osteoporosis
- Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified